UY35070A - ?Sistemas de administración y formulación de fármacos de retención gástrica, y método para su preparación usando carbonato de calcio funcionalizado?. - Google Patents

?Sistemas de administración y formulación de fármacos de retención gástrica, y método para su preparación usando carbonato de calcio funcionalizado?.

Info

Publication number
UY35070A
UY35070A UY0001035070A UY35070A UY35070A UY 35070 A UY35070 A UY 35070A UY 0001035070 A UY0001035070 A UY 0001035070A UY 35070 A UY35070 A UY 35070A UY 35070 A UY35070 A UY 35070A
Authority
UY
Uruguay
Prior art keywords
calcium carbonate
formulation
gastric retention
drugs
preparation
Prior art date
Application number
UY0001035070A
Other languages
English (en)
Inventor
Joachim Schoelkopf
Patrick A C Gane
Maxim Puchkov
Jörg Huwyler
Daniel E Gerard
Rainer Alles
Veronika Anna Eberle
Original Assignee
Omya Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35070(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omya Int Ag filed Critical Omya Int Ag
Publication of UY35070A publication Critical patent/UY35070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Una formulación de fármaco de retención gástrica de flotación inmediata que comprende por lo menos un mineral que comprende carbonato de calcio natural y/o sintético funcionalizado y por lo menos un ingrediente farmacéuticamente activo, y por lo menos un agente de formulación, donde dicho carbonato de calcio natural o sintético funcionalizado es un producto de la reacción de carbonato de calcio natural o sintético con dióxido de carbono y uno o más ácidos, donde el dióxido de carbono se forma in situ mediante el tratamiento ácido y/o es suministrado desde una fuente externa.
UY0001035070A 2012-10-12 2013-10-09 ?Sistemas de administración y formulación de fármacos de retención gástrica, y método para su preparación usando carbonato de calcio funcionalizado?. UY35070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188419.1A EP2719376B1 (en) 2012-10-12 2012-10-12 Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
US201261713691P 2012-10-15 2012-10-15

Publications (1)

Publication Number Publication Date
UY35070A true UY35070A (es) 2014-05-30

Family

ID=47022558

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035070A UY35070A (es) 2012-10-12 2013-10-09 ?Sistemas de administración y formulación de fármacos de retención gástrica, y método para su preparación usando carbonato de calcio funcionalizado?.

Country Status (27)

Country Link
US (2) US9993428B2 (es)
EP (2) EP2719376B1 (es)
JP (1) JP6189445B2 (es)
KR (2) KR20170103989A (es)
CN (1) CN104736145B (es)
AR (1) AR092956A1 (es)
AU (1) AU2013328718B2 (es)
BR (1) BR112015008054A2 (es)
CA (1) CA2885971C (es)
CL (1) CL2015000912A1 (es)
DK (1) DK2719376T3 (es)
ES (1) ES2536836T3 (es)
HR (1) HRP20150558T1 (es)
HU (1) HUE025008T2 (es)
IL (1) IL237829A0 (es)
MX (1) MX365522B (es)
MY (1) MY183859A (es)
PL (1) PL2719376T3 (es)
PT (1) PT2719376E (es)
RS (1) RS54024B1 (es)
RU (1) RU2640914C2 (es)
SG (1) SG11201502196TA (es)
SI (1) SI2719376T1 (es)
SM (1) SMT201500129B (es)
TW (1) TWI564023B (es)
UY (1) UY35070A (es)
WO (1) WO2014057026A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016149385A (ru) 2014-05-30 2018-07-04 Омиа Интернэшнл Аг Спососб производства гранул из поверхностно-прореагировавшего карбоната кальция
EP2949708B1 (en) 2014-05-30 2018-04-04 Omya International AG Method for the production of granules comprising surface-reacted calcium carbonate
EP2957603A1 (en) 2014-06-20 2015-12-23 Omya International AG Method for the production of granules comprising surface-reacted calcium carbonate
EP3034070A1 (en) * 2014-12-18 2016-06-22 Omya International AG Method for the production of a pharmaceutical delivery system
EP3069713A1 (en) * 2015-03-20 2016-09-21 Omya International AG Dispersible dosage form
EP3167879A1 (en) * 2015-11-10 2017-05-17 Evonik Technochemie GmbH Gastric retention active delivery systems
EP3176222A1 (en) 2015-12-01 2017-06-07 Omya International AG Method for the production of granules comprising surface-reacted calcium carbonate
EP3260115A1 (en) * 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
EP3260114A1 (en) 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
EP3269361A1 (en) * 2016-07-14 2018-01-17 Omya International AG Dosage form
EP3275537A1 (en) * 2016-07-25 2018-01-31 Omya International AG Surface-modified calcium carbonate as carrier for transition metal-based catalysts
EP3275946A1 (en) * 2016-07-25 2018-01-31 Omya International AG Post treatment of surface-reacted calcium carbonate with different functional cations
EP3275947A1 (en) 2016-07-25 2018-01-31 Omya International AG Surface-reacted calcium carbonate with functional cations
BR112019013503A2 (pt) 2016-12-31 2020-01-07 Bioxcel Therapeutics, Inc. Uso de dexmedetomidina sublingual para o tratamento da agitação
CN106732678B (zh) * 2017-01-20 2019-05-14 中国科学院西双版纳热带植物园 一种碳基磁性固体酸催化剂及其在生物柴油制备中的应用
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10918597B2 (en) 2017-06-16 2021-02-16 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
CN107522216B (zh) * 2017-07-20 2019-07-23 莆田学院 一种利用咪唑-4,5-二羧酸改性壳聚糖仿生合成微球球霰石的方法
EP4056172A1 (en) 2018-06-18 2022-09-14 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
CN114983981A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
TW202200206A (zh) 2020-04-28 2022-01-01 瑞士商歐米亞國際公司 包含表面反應碳酸鈣作為賦形劑之顆粒
BR112022021818A2 (pt) 2020-04-28 2022-12-13 Omya Int Ag Método para a produção de grânulos de fluxo livre
CN111467317B (zh) * 2020-05-22 2022-03-15 福建海西新药创制有限公司 一种含有阿托伐他汀钙的药物组合物及其制备方法
EP3928859A1 (en) 2020-06-23 2021-12-29 Omya International AG Surface-reacted calcium carbonate in a process for the production of a loaded microcapsule
JP2024525095A (ja) * 2021-07-05 2024-07-09 リフラックス グルメ リミテッド ライアビリティ カンパニー アルギネート、ポリリジン、及び種子防腐剤栄養製品並びに消化補助剤
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3418999A (en) 1964-02-12 1968-12-31 Donald W. Davis Method of swallowing a pill
JPS5512411B2 (es) 1974-03-12 1980-04-02
ZA761305B (en) * 1975-03-17 1977-02-23 Hoffmann La Roche Sustained release formulation
JPS56101694A (en) 1980-01-18 1981-08-14 Nec Corp Semiconductor circuit
US4451260A (en) 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
JPS6143108A (ja) 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
PL149493B1 (en) 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
DE69428707T2 (de) 1993-08-20 2002-07-11 Nippon Shinyaku Co Ltd Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
FR2762213B1 (fr) 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
US20010046473A1 (en) * 1997-04-18 2001-11-29 Jerome Besse Gastric-retained pharmaceutical composition and method for its use
FR2787802B1 (fr) 1998-12-24 2001-02-02 Pluss Stauffer Ag Nouvelle charge ou pigment ou mineral traite pour papier, notamment pigment contenant du caco3 naturel, son procede de fabrication, compositions les contenant, et leurs applications
FR2852600B1 (fr) 2003-03-18 2005-06-10 Nouveau pigment mineral contenant du carbonate de calcium, suspension aqueuse le contenant et ses usages
US20050202084A1 (en) * 2003-07-10 2005-09-15 Prasad Adusumilli Pharmaceutical compositions
FR2881957B1 (fr) * 2005-02-16 2008-08-08 Solvay Comprimes comprenant une substance biologiquement active et un excipient
EP2070991B1 (en) 2007-12-12 2010-09-08 Omya Development AG Process to make surface-reacted precipitated calcium carbonate
WO2010035273A2 (en) * 2008-09-29 2010-04-01 Intec Pharma Ltd. Novel gastroretentive delivery system
EP2168572A1 (en) * 2008-09-30 2010-03-31 Omya Development Ag New controlled release active agent carrier
CA2743639A1 (en) * 2008-11-14 2010-05-20 Patheon Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
RS52297B (en) 2009-06-15 2012-12-31 Omya Development Ag PROCEDURE FOR OBTAINING SURFACE CARBONATE CALCIUM BY THE APPLICATION OF LOW ACID
TWI625129B (zh) 2011-11-10 2018-06-01 歐米亞國際公司 新穎的經塗布控釋活性劑載體

Also Published As

Publication number Publication date
AU2013328718A1 (en) 2015-04-09
DK2719376T3 (en) 2015-06-15
MY183859A (en) 2021-03-17
PL2719376T3 (pl) 2015-08-31
CL2015000912A1 (es) 2016-05-13
CA2885971C (en) 2018-01-02
AU2013328718B2 (en) 2016-07-21
ES2536836T3 (es) 2015-05-29
WO2014057026A1 (en) 2014-04-17
MX365522B (es) 2019-06-06
CN104736145A (zh) 2015-06-24
CN104736145B (zh) 2017-06-23
RS54024B1 (en) 2015-10-30
US9987230B2 (en) 2018-06-05
KR20150044030A (ko) 2015-04-23
SG11201502196TA (en) 2015-04-29
AR092956A1 (es) 2015-05-06
TW201427689A (zh) 2014-07-16
TWI564023B (zh) 2017-01-01
SI2719376T1 (sl) 2015-06-30
JP2015533139A (ja) 2015-11-19
HRP20150558T1 (hr) 2015-07-03
PT2719376E (pt) 2015-07-06
SMT201500129B (it) 2015-07-09
HUE025008T2 (en) 2016-04-28
US20160256393A1 (en) 2016-09-08
MX2015004084A (es) 2015-07-06
BR112015008054A2 (pt) 2017-07-04
RU2015117534A (ru) 2016-11-27
RU2640914C2 (ru) 2018-01-12
KR20170103989A (ko) 2017-09-13
EP2719376B1 (en) 2015-03-04
US9993428B2 (en) 2018-06-12
CA2885971A1 (en) 2014-04-17
IL237829A0 (en) 2015-05-31
JP6189445B2 (ja) 2017-08-30
EP2906200A1 (en) 2015-08-19
EP2719376A1 (en) 2014-04-16
US20150231078A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
UY35070A (es) ?Sistemas de administración y formulación de fármacos de retención gástrica, y método para su preparación usando carbonato de calcio funcionalizado?.
AR092957A1 (es) Formulacion de forma farmaceutica solida de desintegracion veloz que comprende carbonato de calcio funcionalizado y metodo para su fabricacion
BR112014004460A2 (pt) material polimérico para um recipiente isolado
CO2017005500A2 (es) Método para la producción de un sistema de administración farmacéutica
CL2013000423A1 (es) Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.
UY36313A (es) Composición que comprende un carbonato de calcio reaccionado en la superficie como agente antiaglomerante, y método para producirla
BR112015009329A2 (pt) material polimérico para um recipiente isolado
PE20140255A1 (es) Tableta dispersable en forma oral
IN2014MN02214A (es)
PH12014502682A1 (en) Manufacture of degarelix
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
AR076576A1 (es) Procedimiento para estabilizar un suplemento dietetico para facilitar la salud de las articulaciones en seres humanos
BR112012021445A2 (pt) formulação farmacêutica ou neutracêutica.
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
CL2020001926A1 (es) Uso de carbonato de calcio funcionalizado como ingrediente activo.
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin
TH167686B (th) สารตัวยาแบบผสมผสานซึ่งประกอบรวมด้วยเฟนิเลฟรีนและพาราเซตามอล
BR112015017776A2 (pt) formação de estruturas de partículas
TH167686A (th) สารตัวยาแบบผสมผสานซึ่งประกอบรวมด้วยเฟนิเลฟรีนและพาราเซตามอล
MY177091A (en) Sterically stabilized palmitoleic acid liposome
TH128132B (th) องค์ประกอบสำหรับการปลดปล่อยยาฉับพลัน
TH161822A (th) การบำบัดซีบอเรีย
RU2013138895A (ru) Способ повышения воспроизводительной способности быков-производителей
UA36724U (ru) Состав сухой микстуры от кашля
MY175531A (en) Sterically stabilized unsaturated fatty acid liposome

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210617